See the DrugPatentWatch profile for Encorafenib
What’s the patent situation for encorafenib (Braftovi)?
Encorafenib (brand name Braftovi) is protected by patents and related intellectual-property rights that can include primary compound patents and additional coverage such as formulations, dosing regimens, or medical-use claims. The exact patents, their numbers, and their remaining term depend on the country (for example, the U.S. vs. EU vs. UK) and the specific regulatory approvals being protected by those patents.
When does encorafenib patent protection expire?
Patent expiry timelines vary by jurisdiction and by which type of protection you mean:
- Core (compound) patent expiry sets a baseline for generic entry.
- Patents that cover specific formulations or methods of use can extend exclusivity beyond the first expiry date.
- “Regulatory exclusivity” (separate from patents) can also affect when competitors can launch generics or biosimilars or, in some cases, new strengths or line-extensions.
To give an accurate expiry date, you need the jurisdiction and the exact reference product being considered (e.g., U.S. Braftovi vs. an EU member-state authorization), because different patent estates can reach different end dates.
Can generic encorafenib enter before all patents expire?
Often, generic manufacturers do not need all patents to be expired to start the approval pathway for a generic product. But actual market entry can still be blocked if one or more “listed” or otherwise enforceable patents remain in force or are successfully asserted in litigation.
In practice, entry depends on:
- Whether a generic can use a patent carve-out or a successful challenge strategy.
- Whether courts stay enforcement during litigation.
- Whether remaining patents are still valid and enforceable for the specific generic product.
Why are encorafenib patents hard to track?
The encorafenib patent portfolio can be layered:
- Multiple patents can be filed over time, each covering a different aspect of the drug.
- Term adjustments, patent-life extensions, and country-specific rules can shift dates.
- Legal status can change due to assignments, reexaminations, or court decisions.
That means a single “patent expiry date” headline may be misleading unless you specify the exact patent(s) and country.
What should you look up to find the exact encorafenib patent number and expiry date?
Search using the drug name and brand name, then filter by jurisdiction and assignee:
- Drug substance and brand name (encorafenib, Braftovi).
- Assignee(s) owning the patent family.
- Jurisdiction patent databases (e.g., U.S. Patents via USPTO; EU via national/EPO-linked sources; UK and others).
- Company “patent lists” tied to the marketing authorization/labeling in that country.
If you tell me your country, I can narrow it down
Patent timelines depend on jurisdiction. Share the country (and whether you mean U.S., EU-wide, UK, etc.), and I can help you identify the relevant patent(s) to check for encorafenib and the dates those protections typically run through.